Hypertension and endothelial dysfunction in apolipoprotein E knockout mice

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 11, 1999, Pages 2762-2768

  Yang, Renhui ^a   Powell Braxton, Lyn ^a   Ogaoawara, Annie Ko ^a   Dybdal, Noel ^a   Bunting, Stuart ^a   Ohneda, Osamu ^a   Jin, Hongkui ^a  

^a GENENTECH INC   (United States)

Author keywords

Apoe( ) mice; Atherosclerosis; Endothelial dysfunction; Hypertension; Nitric oxide

Indexed keywords

ALLYL ISOTHIOCYANATE; APOLIPOPROTEIN E; CILOSTAZOL; NITRIC OXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY; CONTROLLED STUDY; ENDOTHELIUM; HYPERCHOLESTEROLEMIA; HYPERTENSION; KNOCKOUT MOUSE; LASER DOPPLER FLOWMETRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0032718549     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.11.2762     Document Type: Article

References (46)

1. Mahley RW. Apolipoprotein E: cholesterol transport with expanding role in cell biology. Science. 1988;240:622-630.
2. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992;71:343-353.
3. Zhang SH, Reddick RL, Pierahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992;258:468-471.
4. Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, Maeda N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci USA. 1992;89:4471-4475.
5. Breslow JL. Transgenic mouse models of lipoprotein metabolism and atherosclerosis. Proc Natl Acad Sci USA. 1993;90:8314-8318.
6. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis. Arterioscler Thromb. 1994;14:133-140.
7. Linton MF, Atkinson JB, Fazio S. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science. 267:1034-1037.
8. Reddick RL, Zhang SH, Maeda N. Atherosclerosis in mice lacking APOE: evaluation of lesional development and progression. Arterioscler Thromb. 1994;14:141-147.
9. Seo HS, Lombardi DM, Polinsky P, Powell-Braxton L, Bunting S, Schwartz SM, Rosenfeld ME. Peripheral vascular stenosis in apolipoprotein E-deficient mice. Potential roles of lipid deposition, medial atrophy, and adventitial inflammation. Arterioscler Thromb Vasc Biol. 1997;17:3593-3601.
10. Kaplan NM. Systemic hypertension: mechanisms and diagnosis. In: Braunwald E, ed. Heart Disease, A Textbook of Cardiovascular Medicine. 5th ed. Philadelphia: W.B. Saunders; 1997:825-827.
11. Flavahan NA. Atherosclerosis or lipoprotein-induced endothelial dysfunction: potential mechanisms underlying reduction in EDRF/nitric oxide activity. Circulation. 1992;85:1927-1938.
12. Noll G, Luscher TF. Influence of lipoproteins on endothelial function. Thromb Res. 1994;74(Suppl 1):S45-S54.
13. Harrison DG, Ohara Y. Physiological consequences of increased vascular oxidant stresses in hypercholesterolemia and atherosclerosis: implications for impaired vasomotion. Am J Cardiol. 1995;75:75B-81B.
14. Wennmalm A. Nitric oxide (NO) in the cardiovascular system: role in atherosclerosis and hypercholesterolemia. Blood Pressure. 1994;3:279-282.
15. Andersson TL, Matz J, Ferns GA, Anggard EE. Vitamin E reverses cholesterol-induced endothelial dysfunction in the rabbit coronary circulation. Atherosclerosis. 1994;111:39-45.
16. Hansson GK, Bondjers G. Endothelial dysfunction and injury in atherosclerosis. Acata Med Scand. 1987;(Suppl 715):11-17.
17. Freiman PC, Mitchell GG, Heistad DD, Armstrong ML, Harrison DG. Atherosclerosis impaired muscarinic endothelium-dependent vascular relaxation to acetylcholine and thrombin in primates. Cir Res. 1986;58:783-789.
18. Bossaller C, Habib GB, Yamamoto H, Williams C, Well S, Henry PD. Impaired muscarinic endothelium-dependent relaxation and cyclic guanosine 5"-monophophate formation in atherosclerotic human coronary artery and rabbit aorta. J Clin Invest. 1987;79:170-174.
19. Shimokawa H, Vanhoutte PM. Impaired endothelium-dependent relaxation to aggregating platelets and related vasoactive substances in porcine coronary arteries in hypercholesterolemia and atherosclerosis. Circ Res. 1989;64:900-914.
20. Lippe IT, Stabentheiner A, Holzer P. Participation of nitric oxide in the mustard oil-induced neurogenic inflammation of the rat paw skin. Ear J Pharmacol. 1993;232:113-120.
21. Lippe IT, Stabentheiner A, Holzer P. Role of nitric oxide in the vasodilator but not exudative component of mustard oil -induced inflammation in rat skin. Agents Actions. 1993;38:C22-C24.
22. Wardell K, Jakobbson A, Nilsson GE. Laser Doppler perfusion imaging by dynamic light scattering. IEEE Trans Biomed Engin. 1993;40:309-316.
23. Wardell K, Jakobbson A, Nilsson GE. Prediction of sampling depth and photon pathlength in laser Doppler flowmetry. Med Biol Engin Comp. 1993;31:301-307.
24. Murohara T, Asahara T, Siliver M, Bauters C, Masuda H, Kalka C, Kearney M, Chen D, Symes JF, Fishman MC, Huang PL. Nitric oxide synthase modulates angiogenesis in responses to tissue ischemia. J Clin Invest. 1998;101:2567-2578.
25. Ono I, Gunji H, Suda K, Kaneko F. Effects of cilostazol lotion on blood flow in rabbit skin. J Dermatol Sci. 1994;7:78-83.
26. Tanaka T, Ishikawa T, Hagiwara M, Onoda K, Itoh H, Hidaka H. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology. 1988;36:313-320.
27. Akiyama H, Kudo S, Shimizu T. The absorption, distribution and excretion of a new antithrombotic and vasodilating agent, cilostazol, in rat, rabbit, dog, and man. Drug Res. 1985;35:1124-1140.
28. Ikeda U, Ikeda M, Kano S, Kanbe T, Shimada K. Effect of cilostazol, a cAMP phosphodiesterase inhibitor, on nitric oxide production by vascular smooth muscle cells. Eur J Pharmacol. 1966;314:197-202.
29. Novick AC. Atherosclerotic renovascular disease. J Urol. 1981;126:567-572.
30. Dustan HP. Role of hypertension and its control: experimental aspects. Prog Biochem Pharmacol. 1983;19:177-191.
31. Tobian LJ. Interrelationships of sodium volume, CNS and hypertension. Prog Biochem Pharmacol. 1983;19:208-229.
32. McGill HC, Carey KD, McMahan CA, Marinez YN, Cooper TE, Mott GE, Schwartz CJ. Effects of two forms of hypertension on atherosclerosis in hyperlipidemic baboon. Arteriosclerosis. 1985;5:181-193.
33. Chobanian AV, Lichtenstein AH, Nilakhe V, Haudenschild CC, Drago R, Nickerson C. Influence of hypertension on aortic atherosclerosis in the Watanabe rabbit. Hypertension. 1989;14:202-209.
34. Simon A, Megnien JL, Levenson J. Detection of preclinical atherosclerosis may optimize the management of hypertension. Am J Hypertension. 1997;10:813-824.
35. Trieu VN, Uckum FM. Male-associated hypertension in LDL-R deficient mice. Biochem Bioph Res Comm. 1998;247:277-279.
36. Bonthu S, Heistad DD, Chappell DA, Lamping KG, Faraci FM. Atherosclerosis, vascular remodeling, and impairment of endothelium-dependent relaxation in genetically altered hyperlipidemic mice. Arterioscler Thromb Vasc Biol. 1997;17:2333-2340.
37. Powell-Braxton L, Veniant M, Latvala RD, Hirano K-I, Won WB, Ross J, Dybdal N, Zlot CH, Young SG, Davidson NO. A mouse model of human familial hypercholesterolemia: Markedly elevated low density lipoprotein cholesterol levels and severe atherosclerosis on a low-fat chow diet. Nat Med. 1998;4:934-938.
38. Wardell K. Laser Doppler Perfusion Imaging: Methodology and Skin Applications. Linkoping, Sweden: LJ Foto & Montage; 1994:9-42.
39. Chilian WM, Dellsperger KC, Layne SM, Eastham CL, Armstrong MA, Marcus ML, Heistad DD. Effects of atherosclerosis on the coronary microcirculation. Am J Physiol. 1990;258:H529-H539.
40. Selke FW, Armstrong ML, Harrison DG. Endothelium-dependent vascular relaxation is abnormal in the coronary microcirculation of atherosclerotic primates. Circulation. 1990;81:1586-1593.
41. Zeither AM, Drexler H, Wollschlager H, Just H. Endothelial dysfunction of coronary microvasculature is associated with impaired coronary blood flow regulation in patients with early atherosclerosis. Circulation. 1992; 84:1984-1992.
42. Anderson TJ, Gerhard MD, Meredith IT, Charbonneau F, Delagrange D, Creager MA, Selwyn AP, Ganz P. Systemic nature of endothelial dysfunction in atherosclerosis. Am J Cardiol. 1995;75:71B-74B.
43. Bult H. Nitric oxide and atherosclerosis: possible implications for therapy. Mol Med Today. 1996;2:510-518.
44. Harrison DG. Endothelial dysfunction in atherosclerosis. Bas Res Cardiol. 1994;89(Suppl 1):87-102.
45. Husain S, Andrews NP, Mulcahy D, Panza JA, Quyyumi AA. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation. 1998;97:716-720. ;
46. Galle J, Wanner C. Impact of nitric oxide on renal hemodynamics and glomerular function: modulation by atherogenic lipoproteins? Kidney Blood Press Res. 1996;19:2-15.